Ole Olesen, European Vaccine Initiative (EVI)’s Executive Director, discussed the future funding for global health in the EU framework programme, making the case for continued European investment in the development of #vaccines for diseases of neglected populations, such as #malaria and #tuberculosis. 🦟🦠 🎯 Read the key highlights of the Science|Business session hosted by Impact Global Health and Deutsche Stiftung Weltbevoelkerung (DSW): https://lnkd.in/dnc3EX4Q
A new report by Impact Global Health highlights the immense economic and societal benefits of EU investments in global health research and innovation (R&I)—both for Europe and the world. In collaboration with Impact Global Health, we hosted a session at Science|Business' conference exploring ‘How to accelerate R&D investment for a safer healthier world?’ Read the key takeaways from the session here ➡️ https://lnkd.in/dnc3EX4Q The EU has been a key player in funding neglected disease R&I, contributing 3.5% of global funding (1994-2022). These investments fuel innovation, support critical research, and drive life-saving solutions. The potential impact on #competitiveness, #healthsecurity, and #geopolitical influence is immense. The negotiations for the next research framework programme (FP10) will be key to ensuring adequate investment in global health R&I. Full report: https://lnkd.in/diPugj5V Summary: https://lnkd.in/dF66iSyp